Next Article in Journal
Role of HIF-1α in Alcohol-Mediated Multiple Organ Dysfunction
Previous Article in Journal
Erratum: Traghella, I.; et al. Nontraditional Cardiovascular Biomarkers and Risk Factors: Rationale and Future Perspectives. Biomolecules 2018, 8, 40
Article

Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer

1
Acıbadem Bakırkoy Hospital, Department of Internal Medicine and Medical Oncology, Medical Faculty, Acıbadem Mehmet Ali Aydınlar University, Zeytinlik Mah. Halit Ziya Usaklıgil Cad. No: 1, Bakırkoy, 34140 Istanbul, Turkey
2
Department of General Surgery, Bakırkoy Dr Sadi Konuk Education and Research Hospital, Health Sciences University, 34147 Istanbul, Turkey
3
Department of Medical Oncology, Institute of Oncology, Istanbul University, 34452 Fatih/Istanbul, Turkey
4
Department of Radiology, Bakırkoy Dr Sadi Konuk Education and Research Hospital, Health Sciences University, 34147 Istanbul, Turkey
5
Department of Basic Oncology, Institute of Oncology, Istanbul University, 34452 Istanbul, Turkey
*
Author to whom correspondence should be addressed.
Biomolecules 2018, 8(4), 169; https://doi.org/10.3390/biom8040169
Received: 8 November 2018 / Revised: 26 November 2018 / Accepted: 3 December 2018 / Published: 10 December 2018
Introduction: Pancreatic cancer (PC) is a lethal malignancy. Various diagnostic, predictive, and prognostic biomarkers have been evaluated. This study was conducted to investigate the serum levels of neural precursor cell expressed developmentally downregulated protein 9 (NEDD9) in patients with PC and the relationship between tumor progression and known prognostic parameters. Materials and Methods: Serum samples were obtained on first admission before any treatment. Serum NEDD9 levels were determined using enzyme-linked immunosorbent assay (ELISA). Age- and sex-matched healthy controls were included in the analysis. Results: In a three year period, 32 patients with a pathologically-confirmed diagnosis of PC were enrolled in this study. The median age at diagnosis was 61 years, range 38 to 84 years; the majority of the patients in the group were men (n = 20, 62.5%). The tumor was located in the head of pancreas in 21 (65.6%) patients. Forty-one percent of 17 metastatic patients who received palliative CTx (chemotherapy) were CTx-responsive. The baseline serum NEDD9 levels were significantly higher in patients with PA than in the control group (p = 0.03). Median OS of the whole group were 27 ± 7.3 weeks. Alcohol intake, performance status, and LDH levels were found to be significant prognostic factors (p = 0.006, p < 0.001, and p < 0.001, respectively). However, serum NEDD9 levels had no significantly effect on progression free survival (PFS) and overall survival (OS) (p = 0.71 and p = 0.58, respectively). Conclusions: NEDD9 is identified as a secretory biomarker for PC but it has no prognostic role. View Full-Text
Keywords: NEDD9; pancreatic cancer; serum; diagnostic NEDD9; pancreatic cancer; serum; diagnostic
Show Figures

Figure 1

MDPI and ACS Style

Afsar, C.U.; Karabulut, M.; Karabulut, S.; Tokgoz Ozal, S.; Cikot, M.; Serilmez, M.; Tas, F. Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer. Biomolecules 2018, 8, 169. https://doi.org/10.3390/biom8040169

AMA Style

Afsar CU, Karabulut M, Karabulut S, Tokgoz Ozal S, Cikot M, Serilmez M, Tas F. Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer. Biomolecules. 2018; 8(4):169. https://doi.org/10.3390/biom8040169

Chicago/Turabian Style

Afsar, Cigdem U., Mehmet Karabulut, Senem Karabulut, Safiye Tokgoz Ozal, Murat Cikot, Murat Serilmez, and Faruk Tas. 2018. "Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer" Biomolecules 8, no. 4: 169. https://doi.org/10.3390/biom8040169

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop